Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Andrés Vidal González und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Therapeutic options for children under 12 years with severe atopic dermatitis (AD) who fail dupilumab remain limited. We retrospectively evaluated dupilumab-refractory moderate-to-severe AD treated with off-label upadacitinib in nine children. At week 24, the median Eczema Area and Severity Index (EASI) decreased from 21 to 2, with 78% achieving EASI-75. Pruritus improved rapidly (median numerical rating scale 7 to 1). Treatment was generally well tolerated, with no serious adverse events observed. These findings provide preliminary real-world evidence suggesting that Janus kinase 1 inhibition may represent a potential therapeutic option in selected paediatric patients with severe disease. Larger prospective studies are needed to confirm long-term safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.
ORCID-Profile: Andrés Vidal González, Rafael Escudero Tornero
Zitieren
APA
Vidal González, A., López Alcázar, S., Escudero Tornero, R., Vergara Barria, F. A., Amat Sánchez, J. Á., Maseda Pedrero, R., Feito Rodríguez, M., & De Lucas Laguna, R. (2026). Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag143
Vancouver
Vidal González A, López Alcázar S, Escudero Tornero R, Vergara Barria FA, Amat Sánchez JÁ, Maseda Pedrero R, et al. Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag143
BibTeX
@article{VidalGonzlez2026,
author = {Vidal González, Andrés and López Alcázar, Sergio and Escudero Tornero, Rafael and Vergara Barria, Francisco Antonio and Amat Sánchez, José Ángel and Maseda Pedrero, Rocio and Feito Rodríguez, Marta and De Lucas Laguna, Raúl},
title = {Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag143}
}
EUVIMED